Top

Reactions Weekly

Published in:

01-12-2023 | Acalabrutinib | Case report

Acalabrutinib

Cutaneous lupus erythematosus

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Lin J, et al. 141 Novel emergence of cutaneous lupus erythematosus as adverse effect of Acalabrutinib Therapy for Chronic Lymphocytic Leukemia. Journal of Investigative Dermatology 143 (Suppl.): S356, No. 11, Nov 2023. Available from: URL: https://dx.doi.org/10.1016/j.jid.2023.09.149 [abstract]

Title: Acalabrutinib
Cutaneous lupus erythematosus
Publication date: 01-12-2023
Publisher: Springer International Publishing
Keywords: Acalabrutinib
Lupus Erythematosus
Chronic Lymphocytic Leukemia
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-51320-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Acalabrutinib

Cutaneous lupus erythematosus

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Tacrolimus

Atropine/prednisolone

Antineoplastics

Fentanyl/ketoprofen/morphine

Allopurinol/cotrimoxazole

Multiple drugs